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Abstract
Non-alcoholic fatty liver disease is considered a hepatic 
manifestation of metabolic syndrome (MS). The current 
treatment of non-alcoholic fatty liver disease (NAFLD) 
principally includes amelioration of MS components by 
lifestyle modifications but the lack of success in their 
implementation and sustainment arises the need for 
effective pharmacological agent in fatty liver treat-
ment. Incretins are gut derived hormones secreted 
into the circulation in response to nutrient ingestion 
that enhances glucose-stimulated insulin secretion. 
Glucagon-like peptide-1 (GLP-1) is the most important 
incretin. Its receptor agonist and inhibitors of dipepti-
dyl peptidase-4 (DPP-4) are used in treatment of type 
2 diabetes mellitus. DPP-4 serum activity and hepatic 
expression are shown to be elevated in several hepatic 
diseases. There are several experimental and clinical 
trials exploring the efficacy of incretin based therapies 
in NAFLD treatment. They suggest that GLP-1 ana-
logues might have beneficial effect on hepatic steatosis 
acting as insulin sensitizers and directly by stimulating 
GLP-1 receptors expressed on hepatocytes. The use 
of DPP-4 inhibitors also results in hepatic fat reduction 
but the mechanism of action remains unclear. There is 
growing evidence that incretin based therapies have 
beneficial effects on hepatocytes, however further 
study analysis are needed to assess the long term ef-
fect of incretin based therapies on NAFLD.
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Core tip: Insulin resistance is considered a fundamen-
tal problem in the genesis of hepatic steatosis and the 
pathophysiology of its development. In this review we 
discussed the role of incretin based therapies, includ-
ing glucagon like peptide-1 (GLP-1) analogues and 
dipeptidyl peptidase-4 (DPP-4) inhibitors as a potential 
novel agents in non-alcoholic fatty liver disease treat-
ment comprising experimental and clinical data avail-
able so far which generally suggest that GLP-1 ana-
logues as well as DPP-4 inhibitors might be involved in 
direct pathways of liver fat elimination. To the best of 
our knowledge, this is the first review comprising all 
the data about incretin based therapies in fatty liver 
treatment.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is one of  the 
most common liver disease affecting up to 30% of  the 
general population worldwide[1,2]. It is defined as a chron-
ic liver condition characterized by hepatic fat accumula-
tion in the absence of  other identifiable cause such as 
alcohol abuse, viral or autoimmune hepatitis, alpha-1 an-
titrypsin deficiency, medications like corticosteroids and 
estrogens, and other conditions[3]. In a certain percent-
age of  patients it might occur in a more serious form of  
the disease, non-alcoholic steatohepatitis (NASH) and 
10%-15% of  the patients with NASH develop cirrhosis 
or even hepatocellular carcinoma[4-6]. NAFLD, previously 
named also as a diabetic hepatitis, is highly associated 
with several components of  metabolic syndrome (MS), 
particularly obesity, increased plasma lipid levels (primar-
ily triglycerides), insulin resistance and concomitant glu-
cose intolerance and type 2 diabetes mellitus (T2DM)[4,7,8]. 
The current treatment of  NAFLD principally includes 
ameliorating MS components including weight loss and 
insulin sensitivity improvement by lifestyle modifica-
tions[9-11]. The use of  insulin sensitising agents such as 
metformin and thiazolidinediones has been investi-
gated in numerous clinical trials whose results suggest 
that this approach has modest efficacy for NAFLD 
treatment[12,13]. A recent meta-analysis by Musso et al[14] 
suggests that the use of  TZDs might improve hepatic 
steatosis both in non-diabetic and diabetic patients but 
they also emphasise the possible limit of  TZDs action in 
histological liver injuries more severe than NAFLD, such 
as NASH and also arise the question about importance 
of  insulin sensitivity improvement and its histological 
benefits per se. Moreover, several studies indicate that the 
use of  antioxidants such as vitamin E could improve 
histological features of  NAFLD and NASH[15,16] which 
was recently confirmed by Sanyal et al[17]. Their study re-
sults suggest the vitamin E might have better effects on 
NASH than placebo and even when compared to TZDs 
but also that TZDs might be superior to vitamin E when 
NAFLD is concerned. According to all, the Association 
for the Study of  Liver Diseases (AASLD) guideline for 
diagnosis and NAFLD treatment states that metformin 
has no significant effect on liver histology and it is not 
recommended in treatment in adults with NASH, while 
the use of  pioglitazone (TZD) is recommended with a 
certain degree of  precaution because of  the unknown 
long-term outcomes[18]. Thus, the increasing prevalence 
of  NAFLD and the lack of  success in implementing and 
sustaining lifestyle modifications arises the need for ef-
fective pharmacological agent in fatty liver treatment and 
incretin based therapies might fulfil its role.
The incretines are intestinal mucosa-derived hor-
mones which are secreted into the circulation in re-
sponse to nutrient ingestion that enhance glucose-
stimulated insulin secretion[19]. Glucose-dependent insu-
linotropic polypeptide (GIP) and glucagon-like peptide-1 
(GLP-1) are two identified incretine hormones so far. 
They each contribute equally to incretine effect and fully 
account for such activity in humans[20]. The incretine 
effect comprises enhancement of  insulin biosynthesis 
and secretion in glucose-dependent manner, pancreatic 
β cell mass increasment, appetite suppression and delay 
in gastric emptying[21]. However, as it was established 
that metabolic effects of  GIP are blunted in T2DM and 
the GLP-1 effects are preserved, only GLP-1 remains 
in a great interest of  T2DM and related disorders treat-
ment[20]. As circulating GLP-1 has a half-life about 1-2 
min due to rapid degradation by enzyme dipeptidyl 
peptidase-4 (DPP-4), GLP-1 receptor agonists with 
increased DPP-4 resistance and DPP-4 inhibitors have 
been developed[22]. Recent studies suggest that GLP-1 
receptor agonists and DPP-4 inhibitors might be agents 
of  great interest for hepatic fat reducement so in this re-
view we present the pleiotropic effect of  incretin based 
therapies for NAFLD.
GLP-1 RECEPTOR AGONISTS
GLP-1 receptor agonists represent a novel class of  thera-
pies for T2DM treatment that reflect glucoregulatory 
effects of  endogenous incretin peptide GLP-1. This 
class of  agents usually includes twice daily and once 
weekly formulation of  exenatide and once daily liraglu-
tide which are already implemented in routine clinical 
practice as well as several agents in earlier stages of  clini-
cal development such as lixisenatide, taspoglutide and 
albiglutide[23-26]. Exenatide was the first GLP-1 receptor 
agonist introduced in the clinical practice. It is originally 
derived from the salivary glands of  the Gila monster and 
has 53% homology with human GLP-1. It is adminis-
tered up to 60 min before morning and evening meals 
as indicated as an adjunct to diet and exercise or as an 
add-on ≥ 1 oral hypoglycaemic agent (OHA) therapy[27]. 
Clinical trials with twice-daily exenatide demonstrated 
reductions of  glycated haemoglobin A1c (HbA1c) aver-
aging 1.1%[28-30]. Results from four separate open-label 
studies comparing exenatide therapy with starter insulin 
suggest that twice-daily exenatide at doses of  10 μg was 
similarly effective to either titrated basal or analog mix 
insulin[31-33]. Once weekly exenatide therapy results in a 
greater mean HbA1c reduction compared to twice-daily 
formulation as well as when compared to titrated insulin 
glargine[34].
The once-daily human GLP-1 receptor agonist lira-
glutide was approved by US Food and Drug Administra-
tion (FDA) in the 2010[35]. It has 97% homology with 
human GLP-1 with a single amino acid substitution 
extending its half-life up to 13 h[24]. Data from Liraglu-
tide Effect and Action in Diabetes (LEAD) program 
have demonstrated that liraglutide, when used either as 
monotherapy or as an add-on in combination with ≥1 
OHA, lowers HbA1c by 0.84% to 1.48%[36,37]. Moreover, 
data from LEAD-6, the head-to-head trial versus exena-
tide, 1.8 mg liraglutide once daily resulted in a significant 
greater reduction in HbA1c than exenatide 10 μg bid 
(-1.1% vs -0.8%, P < 0.0001)[38]. So far only exenatide is 
FDA approved for the use in combination with basal 
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insulin. A case-controlled analysis of  addition exenatide 
to insulin therapy resulted in a mean HbA1c decrease 
of  0.6% but also enabled the reduction in insulin dose 
which resulted in weight reduction[39]. Body weight re-
duction, beneficial itself, might also exert favorable ef-
fects on insulin action, cardiovascular disease risk factors 
such as blood pressure and plasma lipids and hepatic fat 
accumulation. A 52-wk study with once-weekly exenatide 
showed a 6-mm Hg systolic blood pressure reduction 
and improvements in the lipid profile in patients with 
T2DM[40]. Sathyanarayana et al[41] examined the effects of  
combined pioglitazone (peroxisome proliferator-activat-
ed receptor-γ (PPAR-γ) agonist) and exenatide therapy 
on hepatic fat content in patients with T2DM and sug-
gested that combined pioglitazone and exenatide therapy 
was associated with a significantly greater decrease in 
hepatic fat (12.1% ± 1.7% to 4.7% ± 1.3%) and plasma 
triglyceride (38%) vs pioglitazone therapy despite the 
lack of  a significant change in body weight (Δ = 0.2 kg). 
However, whether these favourable effects on MS com-
ponents are associated with body weight reduction or are 
a result of  treatment alone warrants further study inves-
tigation. Furthermore, although glucagon-like peptide-1-
based therapy is now routinely used therapy for T2DM, 
there are concerns about risks for pancreatitis and pan-
creatic and thyroid cancer. Previous larges administra-
tive database studies in the United States reported that 
treatment with the GLP-1-based therapies sitagliptin 
and exenatide was associated with increased odds of  
hospitalization for acute pancreatitis[42,43]. GLP-1 recep-
tors are expressed in the exocrine pancreas, and GLP-1 
based therapy has been shown to increase pancreatic 
ductal turnover and acinar to ductal metaplasia[44,45]. In 
addition, low-grade chronic pancreatitis, which increases 
risk of  pancreatic cancer, was noted in rats treated with 
exenatide[46,47]. However, in a recent study GLP-1 analog 
liraglutide did not induce pancreatitis in mice, rats, or 
monkeys when dosed for up to 2 years and at exposure 
levels up to 60 times higher than in humans[48]. In addi-
tion, study including patients with adenocarcinoma and 
with and without diabetes found that insulin-stimulating 
medications such as incretin mimetics did not appear to 
accelerate pancreatic adenocarcinoma development[49]. 
There was also an increase in reported thyroid cancer as 
an adverse event related to exenatide or sitagliptin ther-
apy compared to other oral therapies. In animal models, 
GLP-1 therapy has been shown to lead to C-cell hyper-
plasia, but it is unknown what effects GLP-1 therapy has 
on the human thyroid gland[43].
DPP-4 INHIBITORS
DPP-4 inhibitors are being used clinically in combina-
tion with most other oral antidiabetic agents (including 
sulfonylureas, thiazolidinediones, and metformin) in 
patients failing to achieve adequate glycaemic control, or 
who wish to limit weight gain. A number of  inhibitors 
of  the enzyme DPP-4, which regulates the bioactivity 
of  native GLP-1, have been developed but only few of  
these agents (sitagliptin, vildagliptin, saxagliptin, lina-
gliptin, alogliptin) are available for clinical use[50]. Either 
as monotherapy or an add-on to oral agents, DPP-4 
inhibitors reduce mean HbA1c by approximately 0.5% 
to 0.8%[51-55], a clinical effect somewhat less than that re-
ported with the GLP-1 receptor agonists. DPP-4 inhibi-
tors lower blood glucose without a significant increase 
or reduction in body weight (0.2 to 0.8 kg)[54,55]. Data 
demonstrating extraglycemic effects of  DPP-4 inhibitors 
such as benefits on lipids, blood pressure, or markers 
of  inflammation are very limited. There is no evidence 
that DPP-4 inhibitor therapy results in significant body 
weight, appetite, or food intake reductions. Trials with 
vildagliptin have shown modest improvements in triglyc-
erides and high-density lipoprotein cholesterol (4.8% 
and 10.6%, respectively, in combination with a thiazoli-
dinedione), as well as reductions in systolic and diastolic 
blood pressure[55]. On the opposite to GLP-1 receptor 
agonists, DPP-4 inhibitor therapy is generally well tol-
erated, with no significant gastrointestinal or systemic 
side effects having been reported in clinical trials. A 
favorable tolerability profile means that DPP-4 inhibi-
tor therapy can be safely administered to patients with 
a range of  comorbidities. However, dosage adjustments 
of  sitagliptin are recommended in patients with moder-
ate- to end- stage renal disease[56], because it is cleared 
by the kidney while both sitagliptin and vildagliptin are 
contraindicated in patients with severe hepatic dysfunc-
tion but no sitagliptin dosage adjustment is needed in 
patients with mild-to-moderate hepatic insufficiency[57]. 
Postmarketing reports of  sitagliptin-associated serious 
hypersensitivity reactions, including anaphylaxis, angio-
edema, Stevens-Johnson syndrome, and hepatic enzyme 
elevations have been noted[50,57]. On the other hand, the 
elimination of  another oral DPP-4 inhibitor linagliptin, 
that was approved in the United States and Europe, is 
primarily non-renal and dose adjustment is not required 
even in patients with mild, moderate or severe hepatic 
impairment[50].
PATHOGENESIS AND METABOLIC 
CHANGES IN NAFLD
The pathogenesis of  NAFLD comprises a spectrum of  
genetic factors in combination with obesity and con-
sumption of  products with high glycaemic index and 
rich in saturated fat which also represents a underlying 
mechanism in insulin resistance development[58-60]. In-
ability of  insulin to suppress the lipolysis in white adi-
pose tissue is defined as insulin resistance and is closely 
associated with hepatic fat accumulation[61,62]. The lack 
of  lipolysis suppression leads to increased plasma con-
centration of  free fatty acids (FFA) which then disrupts 
the hepatic balance in FFA influx and oxidation and 
becomes the main source of  hepatic triglycerides in 
NAFLD[63]. Therefore, insulin resistance in white adi-
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pose tissue might contribute to hepatic fat accumulation. 
Additionally, the use of  insulin sensitizers thiazolidne-
diones, the peroxisome-proliferator-activated receptors γ 
(PPARγ) agonists has shown to decrease liver fat content 
by 40% despite the unaltered liver PPARγ in NAFLD[64]. 
Hepatocytes in human NAFLD contain high amount of  
saturated fatty acids and saturated fatty acid containing 
triglycerides which cannot all be contributable to FFA 
increased influx[65] but also to hepatic de novo lipogenesis 
which is significantly increased in NAFLD[63]. Higuchi 
et al[66] revealed that hepatic gene expression of  sterol 
regulatory element-binding protein (SREBP) 1c, which 
is the key transcriptional activator of  lipogenic genes as 
well as acetyl-CoA carboxylases (ACCs) and fatty acid 
synthetase (FAS), is increased in subjects with as com-
pared to those without NAFLD while Kotronen et al[65] 
reported that the activity of  lipogenic enzyme stearoyl-
CoA desaturase 1 (SCD1) is increased which leads to 
decrease in long polyunsaturated fatty acid content.
In addition to white adipose tissue and skeletal 
muscle, the liver is the main site of  insulin action[67]. 
Insulin resistance in liver usually accompanies insulin 
resistance in white adipose tissue and can be observed 
in the glucose and lipid metabolism. In the fasting state 
insulin restrains hepatic glucose production in order to 
maintain glucose concentration homeostasis. In insulin 
resistance state the ability of  insulin to inhibit hepatic 
glucose production is impaired leading to higher fasting 
plasma glucose concentration and consequent hyperinsu-
linemia[67,68]. Another insulin action in liver is to restrain 
the production of  very low density lipoprotein (VLDL)[69] 
so the insulin resistant liver overproduces triglyceride 
rich VLDL in the fasting state[61,70] which then leads to 
hypertriglyceridemia and low high density lipoprotein 
(HDL) concentration that can be found in subjects with 
MS and NAFLD[71,72]. In accordance with previous, insu-
lin resistance is the central pathophysiological phenom-
enon of  MS associated with the development of  type 2 
diabetes and NAFLD[73]. Moreover, although insulin re-
sistance is not a underlying cause of  some other disease 
like autoimmune type 1 diabetes, the presence of  insulin 
resistance in those subjects are independently associated 
with markers of  NAFLD[74] (Figure 1).
INCRETIN BASED THERAPIES-AN 
INDIRECT ACTION
GLP-1 receptor agonists (exenatide, liraglutide) are agents 
developed for T2DM treatment with a primarily role of  
maintenance of  glucose homeostasis. However, their 
pleiotropic effect on appetite, weight, blood pressure, 
cardiovascular function and central nervous system have 
been reported[75]. The indirect action of  GLP-1 receptor 
agonists on NAFLD pathophysiology might be observed 
from at least two aspects: the appetite suppression and 
weight reduction as well as direct and indirect improve-
ment in insulin sensitivity since it has been proposed that 
weight reduction might improve insulin sensitivity[36,76-78]. 
GLP-1 receptor activation in hypothalamus reduces ap-
petite and leads to weight loss[79]. When administered as 
mono-therapy, exenatide is associated with weight loss 
of  approximately 3 kg over 24 wk of  treatment in obese 
T2DM population[80] while 52-wk liraglutide monother-
apy provided dose dependent reduction in mean body 
weight of  1.9 and 2.3 kg, respectively[36]. Similar effect 
was observed with non-diabetic healthy population treat-
ed with exenatide[81] and it was shown that even modest 
weight loss of  5%-10% of  body weight decreases liver 
fat up to 40%-80% in non-diabetic subjects and T2DM 
patients[82-85]. On the opposite, DPP-4 inhibitors show no 
significant effect on weight loss[52,84] and the assumption 
that they cannot provide this indirect beneficial effect on 
hepatic fat reduction becomes obvious. As we already 
discussed, insulin resistance in white adipose tissue is 
one of  the main steps in NAFLD development. Data 
from the study of  Klonoff et al[85] as well as Buse et al[86] 
suggest that exenatide treatment in T2DM patients leads 
to significant alanine aminotransferase (ALT) and intra-
hepatic fat reduction in correlation to insulin resistance 
decreasment.
There are several studies suggesting that GLP-1 recep-
tor analogues directly affect peripheral insulin sensitivity; 
Egan et al[77] used modified clamp and demonstrated that 
GLP-1 infusion increases glucose uptake without sig-
nificant rise independent of  changes in insulin secretion 
in ten healthy obese volunteers while the experimental 
results suggest the neutral action on lipolysis in white 
adipose tissue which then diminishes the possibility 
of  their beneficial effect on NAFLD pathogenesis per 
se[87]. Treatment with DPP-4 inhibitors vildagliptin and 
sitagliptin have also demonstrated favourable effects on 
postprandial elevations of  triglycerides, ApoB-48 and 
FFA levels[88,89]. The DPP-4 inhibition was also reported 
to enhance the antilipolytic effect of  neuropeptide Y 
(NPY) in human abdominal adipocytes which could 
have indirect mechanism on hepatic fat reducing FFA 
influx in hepatocytes[90]. However, it should be kept in 
mind that NPY causes abdominal fat accumulation, one 
of  the major steps in hepatic insulin resistance develop-
ment[91]. It is possible that DPP-4 inhibitors might have 
indirect mechanism in inhibition of  hepatic fat accumu-
lation serve as local endogenous GLP-1 concentration 
enhancer because they have no influence on gastric emp-
tying or weight loss (Figure 1).
INCRETIN BASED THERAPIES-A DIRECT 
ACTION
The implementation of  GLP-1 agonists in clinical prac-
tice, primary in treatment of  T2DM, revealed data sug-
gesting their potency in intrahepatic liver fat and bio-
marker reduction independently of  glycaemic or weight 
reduction[40,92,93]. However, it was unclear whether this 
effect could be contributable to GLP-1 agonists itself  
because there was no evidence of  molecular mecha-
nism that could explain this beneficial effect of  GLP-1 
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agonists. Several mouse models of  NAFLD, based on 
genetic mutations or diet, were developed in order to 
serve as a preclinical platform to evaluate GLP-1 actions 
in liver[94]. Ding et al[95] suggested that GLP-1 analogue 
exendin-4 improves insulin resistance in ob/ob mice and 
significantly reduces hepatic lipid stores evaluated by 
histological improvement and improved of  ALT values. 
They also revealed that exendin-4 has direct action on 
hepatocytes and subsequently results in a gene profile 
that is conducive in reduction in fatty acid synthesis and 
triglyceride storage in hepatocytes: increased mRNA for 
both PPARα along with decreased mRNA expression 
for SREBP-1c and ACC1. In support to those data Sam-
son et al[96] demonstrated in diet induced obesity model 
mice that exendin-4 treatment reverses hepatic steatosis 
and decreases hepatic expression of  genes involved in 
de novo fatty acid synthesis, including ACC1, fatty acid 
synthase (FAS) and SCD1. The question arises whether 
GLP-1 impairs hepatocyte de novo lipogenesis and/or en-
hances β-oxidation of  fatty acids. Svegliati-Baroni et al[97] 
reported that exendin-4 treatment improves the expres-
sion of  PPARα and its downstream target genes: acyl-
Coenzyme A oxidase (ACOX) and carnitine palmitoyl-
transferase 1 A (CPT1A) in hepatocytes isolated from 
rats with non-alcoholic steatohepatitis. ACOX is the rate 
limiting enzyme in peroxisomal β oxidation while CP-
T1A is the key enzyme in initial transport of  fatty acids 
into mitochondria for β oxidation. However, it was still 
unclear whether GLP-1 receptors were present in hu-
man liver and whether they were biologically active. Lee 
et al[98] reported that exendin-4 increases expression of  
GLP-1 receptor in a dose dependent manner in human 
hepatoma cell lines while Gupta et al[99] demonstrated 
that GLP-1 receptor is present in human hepatocytes 
and also provided molecular mechanism to explain the 
signal effectors of  GLP-1 in its potential role in hepa-
tocyte TG reduction by up regulating key elements of  
the insulin receptor substrate-2 (IRS-2) in hepatocytes. 
They suggest that GLP-1 based proteins should be anal-
ysed as insulin sensitizing agents in hepatocytes and that 
higher dose distribution of  GLP-1 analogues should be 
considered in T2DM patients in order to reduce hepatic 
steatosis. There is also evidence that GLP-1 receptor 
agonists could improve hepatic steatosis by modulating 
fibroblast growth factor-21 (FGF-21) signalisation. In 
rodents, FGF21 is predominantly produced in the liver, 
where it enhances hepatic fat oxidation reduces triacylg-
lycerol levels and hepatic steatosis but also increases adi-
pocyte insulin sensitivity and regulates lipolysis in white 
adipose tissue, and improves glucose tolerance[100]. It has 
been suggested that these changes may occur through 
the effects of  FGF21 on AMP-activated protein kinase 
(AMPK) activity. In the liver AMPK activates fatty acid 
oxidation via activation of  PGC1α as well as its ef-
fects on other enzymes of  lipogenesis described above 
(e.g., SREBP and FAS)[101]. Dushay et al[102] have shown 
that liver FGF21 protein levels and RNA are increased 
in association with hepatic steatosis in obese humans 
with NAFLD. In mouse models of  obesity, circulating 
FGF21 levels are elevated and FGF21 signalling in the 
liver and white adipose tissue is impaired[103]. Samson et 
al[104] suggested that exenatide treatment in T2DM pa-
tients and a diet induced obese mouse is associated with 
a decrease in FGF21 and hepatic fat, and an increase in 
hepatic AMPK and ACC phosphorylation explained as a 
possible sign of  improved FGF21 resistance in the liver. 
Therapy with another GLP-1 agonist, liraglutide, in sub-
jects with metabolic syndrome and T2DM is also associ-
ated with improvement of  liver inflammation, alteration 
of  liver fibrosis, and reduction of  body weight[105,106]. 
Recent data indicate that endoplasmic stress is a major 
player in the progression of  fatty liver to more aggres-
sive lesions and treatment with liraglutide reduces steato-
sis and endoplasmic stress in high fat diet fed mice and 
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Figure 1  The pathogenesis of non-alcoholic fatty liver disease and the possible effect of incretin system components in treatment. Modified according to 
Dowman et al[63]. ACC: Acetyl-CoA carboxylase; DPP-4: Dipeptydil peptidase-4; GLP-1: Glucagon-like peptide-1; FFA: Free fatty acid; FAS: Fatty acid synthetase; 
SREPB1c: Sterol regulatory element-binding protein.
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Firneisz et al[108] reported a link between the serum 
DPP-4 activity and NAFLD in a small cross-sectional 
study whose results showed correlation of  sDPP-4 activ-
ity with liver tests ALT, γGT, and less significantly ALP. 
Surprisingly, they reported that sDPP-4 activity was not 
increased in the T2D patients and there was no correla-
tion between sDPP-4 and HbA1C values nor between 
sDPP-4 and fasting plasma glucose that were reported 
earlier in T2DM patients[109,110]. The positive correlation 
found among γGT, ALT and serum DPP-4 activities 
in NAFLD suggested that the excess DPP-4 found in 
the serum is of  hepatic origin. Later on hepatic DPP-4 
mRNA expression levels was analysed by real-time PCR 
using liver biopsy samples from 17 NAFLD patients and 
10 healthy subjects by Miyazaki et al[111]. They showed 
that hepatic DPP-4 mRNA expression was significantly 
greater in NAFLD patients than in control subjects and 
that DPP-4 expression levels negatively correlated with 
homeostasis model assessment-estimated insulin resis-
tance (HOMA-IR) index and positively correlated with 
serum cholesterol levels which clearly implicated hepatic 
DPP-4 in this disease. In addition, serum DPP-4 activity 
and hepatic DPP-4 expression are shown to be corre-
lated with hepatic steatosis and NAFLD grading which 
indicates that it might be associated with hepatic lipo-
genesis and liver injury[112]. Iwasaki et al[113] evaluated the 
effect of  sitagliptin administered in dose of  50 mg/body 
per day for 4 mo in 30 NAFLD patients with T2DM 
and reported a significant improvement of  the serum 
levels of  HbA1c and liver enzymes at 4, 8, 12 and 16 
wk after the start of  sitagliptin treatment and therefore 
concluded that sitagliptin might be considered as a novel 
therapeutic agent for NAFLD treatment. Moreover, 
it was recently reported that sitagliptin, DPP-4 inhibi-
tor, ameliorated hepatic steatosis in 67-year-old Asian 
woman with refractory NAFLD after 3 mo treatment[114]. 
Considering some previously reported data about DPP-4 
deficient rats showing lower levels of  hepatic proinflam-
matory and profibrotic cytokines which often represents 
a “second hit” in NAFLD development[115], the role of  
DPP-4 inhibition in NAFLD treatment seams uncon-
tested whether based on direct effect of  DPP-4 inhibi-
tion or enhancement of  endogenous GLP-1 action[116] 
(Figure 1).
CONCLUSION
In this review we described that insulin resistance was 
a fundamental problem in the genesis of  hepatic ste-
atosis and the pathophysiology of  its development. We 
discussed the role of  incretin based therapies, includ-
ing GLP-1 analogues and DPP-4 inhibitors as a po-
tential novel agents in NAFLD treatment comprising 
experimental and clinical data available so far. GLP-1 
analogues are known to improve insulin resistance and 
are even more attractive because they have anorexigenic 
potential leading to weight loss, serum glucose and lipids 
improvement. Those, as well as DPP-4 inhibitors might 
also be involved in direct pathways of  liver fat elimina-
tion. A growing body of  literature suggests that GLP-1 
and DPP-4 activity have numerous effects on the cells 
of  various organs. The data regarding GLP-1 and DPP-4 
inhibitors action on hepatocytes are convincing, but 
so far only T2DM patients with NAFLD/NASH have 
been studied with incretin analogues or DPP-4 inhibi-
tors, therefore, the conclusions of  this review only can 
be applied to T2DM patients suffering for NASH, and 
not for the nondiabetic-NAFLD patients. further study 
analysis are needed in order to aces the long term effect 
of  incretin based therapies on NAFLD.
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